These data indicate that the benefit of CXCR2 inhibition in mCRPC is not limited to tumours in which the PTEN–PI3K pathway is activated, but whether deleterious alterations in TP53 or cyclin-dependent kinase (CDK) inhibitors confer resistance warrants further evaluation. This evidence concerns the gene CXCR2 and neoplasm.